China
Africa
Explore chapters and articles related to this topic
Acute Myeloid Leukemia An Introduction
Published in Wojciech Gorczyca, Atlas of Differential Diagnosis in Neoplastic Hematopathology, 2014
Metastatic carcinomas including breast carcinoma, small cell carcinoma, neuroblastoma, and alveolar rhabdomyosarcoma are distinguished from AML by their specific immunophenotypic profile. Plasmacytoid dendritic cell lymphoma/leukemia [blastic natural killer (NK) cell lymphoma/leukemia] is positive for CD4 and CD56, and does not coexpress CD13, CD33, and CD117 (rare cases of blastic NK cell lymphoma/leukemia may be positive for either CD33 or CD117).
Decrease in the Frequency of Circulating CD56+CD161+ NK Cells in Human Visceral Leishmaniasis
Published in Immunological Investigations, 2018
Ambak Kumar Rai, Chandreshwar Prasad Thakur, Prabin Kumar, Sheetal Saini, Amit Kumar Kureel, Smita Kumari, Tulika Seth, Dipendra Kumar Mitra
Importantly, we have observed another subset of NK cells having CD161–CD56+ phenotype in CD3– compartment of blood sample of healthy subjects. However, this population remains unaltered in VL patients as compared with HCs. More importantly, it forms the second major subset of NK cells in blood sample of healthy and diseased subjects. Humans NK cells majorly can be divided into two subsets on the basis of CD56 expression: CD3–CD161+CD56+ dim and CD3–CD161+CD56+ bright. It is believed that CD56bright NK cells give rise to more mature CD56dim subset (Moretta, 2010; Romagnani et al., 2007). To the best of our knowledge, CD161–CD56+ NK cells in CD3– population are not yet reported in the literature. However, such phenotype is reported in certain abnormal conditions like lymphoproliferative disorder, i.e., blastic NK-cell lymphoma and nasal NK-cell lymphoma (Mori et al., 2001). It would be interesting to further study this population and understand its relevance in NK-cell-mediated immune response.